Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Aurinia Pharmaceuticals to related businesses based on the strength of its dividends, analyst recommendations, valuation, institutional ownership, earnings, risk and profitability.
Profitability
This table compares Aurinia Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
| Aurinia Pharmaceuticals Competitors | -12,359.35% | -203.09% | -30.93% |
Valuation & Earnings
This table compares Aurinia Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Aurinia Pharmaceuticals | $283.05 million | $287.20 million | 7.14 |
| Aurinia Pharmaceuticals Competitors | $698.13 million | $10.43 million | -15.32 |
Aurinia Pharmaceuticals’ competitors have higher revenue, but lower earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
Aurinia Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals’ competitors have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.
Institutional and Insider Ownership
36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and price targets for Aurinia Pharmaceuticals and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
| Aurinia Pharmaceuticals Competitors | 9847 | 15133 | 45510 | 1589 | 2.54 |
Aurinia Pharmaceuticals presently has a consensus price target of $17.33, suggesting a potential upside of 6.01%. As a group, “Biotechnology” companies have a potential upside of 100.30%. Given Aurinia Pharmaceuticals’ competitors higher probable upside, analysts plainly believe Aurinia Pharmaceuticals has less favorable growth aspects than its competitors.
Summary
Aurinia Pharmaceuticals beats its competitors on 8 of the 13 factors compared.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
